V
The startup has developed a virus discovery platform that identifies and catalogs oncolytic viral and vaccine species to selectively target and destroy cancer cells while stimulating anti-cancer immune responses. This approach minimizes side effects on healthy cells, providing a more effective treatment option for cancer patients.
Updated 3 months ago
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a virus discovery platform that identifies and catalogs oncolytic viral and vaccine species to selectively target and destroy cancer cells while stimulating anti-cancer immune responses. This approach minimizes side effects on healthy cells, providing a more effective treatment option for cancer patients.